GlycoMimetics Inc (GLYC) - Total Liabilities
Based on the latest financial reports, GlycoMimetics Inc (GLYC) has total liabilities worth $2.62 Billion USD as of March 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of GlycoMimetics Inc to evaluate the company's liquid asset resilience ratio.
GlycoMimetics Inc - Total Liabilities Trend (2011–2024)
This chart illustrates how GlycoMimetics Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see GLYC asset base.
GlycoMimetics Inc Competitors by Total Liabilities
The table below lists competitors of GlycoMimetics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Unibap AB
ST:UNIBAP
|
Sweden | Skr28.97 Million |
|
REC Silicon ASA
OL:RECSI
|
Norway | Nkr582.30 Million |
|
ABM Fujiya Bhd
KLSE:5198
|
Malaysia | RM379.24 Million |
|
Dien Quang JSC
VN:DQC
|
Vietnam | ₫447.81 Billion |
|
KINGFISH COMPANY EO -01
F:93G
|
Germany | €122.14 Million |
|
SSH GROUP LTD
F:JRSA
|
Germany | €31.15 Million |
|
TDH Holdings Inc
NASDAQ:PETZ
|
USA | $9.57 Million |
|
Ainos Inc
NASDAQ:AIMD
|
USA | $16.28 Million |
Liability Composition Analysis (2011–2024)
This chart breaks down GlycoMimetics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See GlycoMimetics Inc net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.29 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.78 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.44 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how GlycoMimetics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for GlycoMimetics Inc (2011–2024)
The table below shows the annual total liabilities of GlycoMimetics Inc from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $5.78 Million | -16.29% |
| 2023-12-31 | $6.90 Million | -22.28% |
| 2022-12-31 | $8.88 Million | -30.31% |
| 2021-12-31 | $12.74 Million | -12.80% |
| 2020-12-31 | $14.61 Million | +6.13% |
| 2019-12-31 | $13.77 Million | +46.87% |
| 2018-12-31 | $9.38 Million | +5.55% |
| 2017-12-31 | $8.88 Million | +25.32% |
| 2016-12-31 | $7.09 Million | -11.30% |
| 2015-12-31 | $7.99 Million | +23.67% |
| 2014-12-31 | $6.46 Million | +171.90% |
| 2013-12-31 | $2.38 Million | -59.67% |
| 2012-12-31 | $5.89 Million | -71.19% |
| 2011-12-31 | $20.45 Million | -- |
About GlycoMimetics Inc
GlycoMimetics, Inc. engages in the discovery and development of therapies for cancers and inflammatory diseases in the United States. The company was founded in 2003 and is based in Monrovia, Maryland.